HD-OPM Archive
Topics › Infections & vaccines

BCG vaccine may remodel brain immunity and shift Alzheimer's markers

Louis Nervegna · Jul 05, 2026 · ♥ 5 reactions · 0 comments · original Facebook post
Infections & vaccinesBrain health & dementia
AI summary & key facts

Mass General Brigham research suggests BCG vaccine remodels the brain's immune environment over 12 months, offering an explanation for observed links between vaccines and lower Alzheimer's risk.

The Bacillus Calmette-Guérin (BCG) vaccine may lower the risk for Alzheimer’s, according to new research at MGH Brigham Hospital in Boston. This vaccine is typically given to prevent tuberculosis.

The study also provides some mechanistic explanation why other vaccines— such as shingles, rsv, and influenza— have also been associated with lower risk for Alzheimer’s and other neurological diseases.

Quoted:

New research led by Mass General Brigham investigators suggests that the Bacillus Calmette-Guérin (BCG) vaccine—which is delivered through the skin to prevent tuberculosis—may remodel the human brain's immune environment, offering a potential biological explanation for previously observed associations between BCG vaccination and lower Alzheimer's disease risk. Findings are published in Communications Medicine

The yearlong study found that BCG promoted increased responsiveness in immune cells surrounding the brain and modified Alzheimer's-related biomarkers in older adults without evidence of Alzheimer's pathology, but not in those with biomarker evidence of the disease.

"The immune system and the brain may be far more connected than we once thought," said senior and co-corresponding author Steven Arnold, MD, managing director of the Interdisciplinary Brain Center at Mass General Brigham Neuroscience Institute. "The next step is to test this rigorously in larger, controlled studies, particularly in prevention, where the hope would be to preserve brain health before significant Alzheimer's disease develops."

Over the last two decades, researchers at Mass General Brigham have been studying multiple "off-target" benefits of the BCG vaccine in autoimmunity and infection, including ongoing phase 3 clinical trials in type 1 diabetes and past phase 2 and phase 3 trials in COVID-19. Prior research involving preclinical models, retrospective studies and randomized clinical trials has suggested that BCG can also reduce Alzheimer's risk and bring about trained immunity, boosting defenses against unrelated infections and correcting blood sugars.

“Vaccines have traditionally been viewed through the lens of infectious disease prevention," said Weinberg, who contributed to the study while working as a research scientist at Mass General Brigham and is now an employee at AbbVie. "Although more research is needed, these findings suggest they may also influence biological processes involved in brain aging and neurodegenerative disease."

#bcgHD #vaccinesHD #alzheimersHD #mghbrighamHD #shinglesHD #rsvHD #fluHD #tuberculosisHD

medicalxpress.comBcg vaccine rewire brain immunityNew research led by Mass General Brigham investigators suggests that the Bacillus Calmette-Guérin (BCG) vaccine—which is delivered through the skin to prevent tuberculosis—may remodel the human brain's immune environment, offering a potential biological explanation for previously observed assoc...medicalxpress.com

Research cited

← newer: Mayo Clinic recruiting for beetroot juice, sleep and blood polder: Glutathione supplements are probably a bad idea long term →